The additional doses are a result of the European Commission’s expanded advance purchase agreement, which brings the total number of doses delivered to the EU to 600 million.
Pfizer and BioNTech announced on April 19, 2021 that they will supply an additional 100 million doses of their COVID-19 vaccine, COMIRNATY, to the European Union (EU) member states in 2021.
The additional doses are a result of the European Commission’s (EC) expanded advance purchase agreement, which brings the total number of doses delivered to the EU to 600 million, Pfizer said in a company press release.
“We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” said Albert Bourla, chairman and CEO, Pfizer, in the press release. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2 [second quarter], a four-fold increase on Q1’s [first quarter’s] agreed quantity.”
“The additional 100 million doses from this option exercise will further help to support the acceleration of the vaccination campaigns throughout the EU. We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for COMIRNATY that we have agreed to date globally,” added Sean Marett, chief business and chief commercial officer, BioNTech, in the press release.
Source: Pfizer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.